8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
May 7, 2026·SEC
Material company update
Apr 22, 2026·SEC
Mind Medicine (MindMed) Inc.(MNMD)Earnings, Financials & Key Ratios
MNMD•NASDAQ
Price updated May 18, 2026
AboutMind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.Show more
- Revenue$0
- EBITDA-$178M-72.5%
- Net Income-$184M-69.1%
- EPS (Diluted)-2.06-1273.3%
- ROE-64.06%+5.8%
MNMD Key Insights
Mind Medicine (MindMed) Inc. (MNMD) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 94 (top 6%)
- ✓Share count reduced 87.3% through buybacks
- ✓Trading near 52-week high
✗Weaknesses
- ✗Profits declining 40.1% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when MNMD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MNMD Price & Volume
Mind Medicine (MindMed) Inc. (MNMD) stock price & volume — 10-year historical chart
Loading chart...
MNMD Growth Metrics
Mind Medicine (MindMed) Inc. (MNMD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-206.01%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-167.34%
Return on Capital
10 Years-54.58%
5 Years-62.35%
3 Years-62.5%
Last Year-52.24%
MNMD Recent Earnings
Mind Medicine (MindMed) Inc. (MNMD) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)
Q2 2026Latest
Mar 5, 2026Metric
Actual
Est
EPS
$0.51-6.3%
$0.48
Rev
—
—
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.56-16.7%
$0.48
Rev
—
—
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.78-50.0%
$0.52
Rev
—
—
Q3 2025
Jul 31, 2025Metric
Actual
Est
EPS
$0.50-31.6%
$0.38
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 5, 2026 | $0.51vs $0.48-6.3% | — |
| Q1 2026 | Feb 26, 2026 | $0.56vs $0.48-16.7% | — |
| Q4 2025 | Nov 6, 2025 | $0.78vs $0.52-50.0% | — |
| Q3 2025 | Jul 31, 2025 | $0.50vs $0.38-31.6% | — |
Based on last 12 quarters of dataView full earnings history →
MNMD Peer Comparison
Mind Medicine (MindMed) Inc. (MNMD) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CMPS | 1.2B | 12.53 | -4.07 | -151.02% | ||||
 ATAI | 1.49B | 4.06 | -1.40 | 12.28% | -190.19% | -366.21% | 0.01 | |
 CYBN | 303.86M | 6.09 | -13.66 | -81% | ||||
 MGRX | 3.33M | 0.33 | -0.16 | -25.96% | -46.33% | -120.72% | 0.02 | |
 SILO | 5.54M | 6.12 | -0.82 | -67.17% | -88.41% | |||
 LWAY | 388.62M | 25.43 | 28.57 | 13.74% | 6.54% | 17.76% | 0.01 | |
 ENVB | 764.17K | 1.28 | -0.04 | -220.99% | ||||
 JAZZ | 14.09B | 224.66 | -38.47 | 4.88% | 0.66% | 0.71% | 1.26 |
Compare MNMD vs Peers
Mind Medicine (MindMed) Inc. (MNMD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MNMD Income Statement
Mind Medicine (MindMed) Inc. (MNMD) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Aug'17 | Aug'18 | Aug'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 5.5K | 6.68K | 6.68K | 0 | 0 | 3.22M | 3.16M | 527K | 0 | 0 |
COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
Gross Profit | -5.5K▲ 0% | -6.68K▼ 21.5% | -6.68K▼ 0.0% | 0▲ 100.0% | 0▲ 0% | -3.22M▲ 0% | -3.16M▲ 1.9% | -527K▲ 83.3% | 0▲ 100.0% | 0▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - | - | - |
Gross Profit Growth % | - | -21.46% | -0.03% | 100% | - | - | 1.89% | 83.33% | 100% | - |
Operating Expenses | 1.23M | 855.26K | 461.5K | 33.03M | 93.85M | 66.33M | 90.7M | 103.39M | 166.31M | 193.37M |
OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Selling, General & Admin | 1.23M | 855.26K | 461.5K | 14.4M | 59.06M | 30.16M | 41.74M | 38.62M | 48.64M | 57.58M |
SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
Research & Development | 0 | 0 | 0 | 18.63M | 34.79M | 36.17M | 48.96M | 65.3M | 117.67M | 135.79M |
R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -527K | 0 | 0 |
Operating Income | -1.24M▲ 0% | -861.94K▲ 30.2% | -468.18K▲ 45.7% | -33.03M▼ 6955.0% | -93.85M▼ 184.1% | -66.33M▲ 29.3% | -93.87M▼ 41.5% | -103.92M▼ 10.7% | -166.31M▼ 60.0% | -193.37M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - | - | - |
Operating Income Growth % | -1010.23% | 30.21% | 45.68% | -6954.98% | -184.15% | 29.33% | -41.51% | -10.71% | -60.04% | - |
EBITDA | -1.23M | -855.26K | -461.5K | -32.82M | -91.24M | -63.15M | -90.7M | -103.39M | -178.31M | -191.11M |
EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
EBITDA Growth % | -1005.28% | 30.45% | 46.04% | -7012.45% | -177.96% | 30.78% | -43.63% | -13.99% | -72.47% | -154.22% |
D&A (Non-Cash Add-back) | 5.5K | 6.68K | 6.68K | 206.3K | 2.62M | 3.18M | 3.16M | 527K | 0 | 6.75K |
EBIT | -1.51M | -857.94K | -1.12M | -33.77M | -93.85M | -66.33M | -95.73M | -106.4M | -178.31M | -211.44M |
Net Interest Income | 0 | 0 | 0 | -164K | -359K | 0 | 4.66M | 9.28M | 5.48M | 2.52M |
Interest Income | 8.4K | 4K | 0 | 0 | 0 | 1.5M | 5.58M | 11.56M | 10.96M | 11.98M |
Interest Expense | 0 | 0 | 0 | 164K | 359K | 1.5M | 920K | 2.28M | 5.48M | 9.47M |
Other Income/Expense | 8.4K | 4K | -647.63K | -907K | -339K | 9.54M | -1.87M | -4.76M | -17.48M | -44.17M |
Pretax Income | -1.23M▲ 0% | -857.94K▲ 30.1% | -1.12M▼ 30.1% | -33.94M▼ 2941.5% | -94.19M▼ 177.6% | -56.8M▲ 39.7% | -95.73M▼ 68.6% | -108.68M▼ 13.5% | -183.79M▼ 69.1% | -237.54M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
Income Tax | -2 | -2 | -4 | 0 | -1.16M | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 1.23% | 0% | 0% | 0% | 0% | 0% |
Net Income | -1.23M▲ 0% | -857.94K▲ 30.1% | -1.12M▼ 30.1% | -34.1M▼ 2956.2% | -93.04M▼ 172.8% | -56.8M▲ 39.0% | -95.73M▼ 68.6% | -108.68M▼ 13.5% | -183.79M▼ 69.1% | -237.54M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - | - | - |
Net Income Growth % | -581.9% | 30.06% | -30.06% | -2956.18% | -172.82% | 38.95% | -68.55% | -13.52% | -69.12% | -206.01% |
Net Income (Continuing) | -1.23M | -857.94K | -1.12M | -33.94M | -93.04M | -56.8M | -95.73M | -108.68M | -183.79M | -237.54M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -4.85▲ 0% | -2.74▲ 43.5% | -2.94▼ 7.3% | -1.92▲ 34.7% | -3.40▼ 77.1% | -1.84▲ 45.9% | -2.44▼ 32.6% | -0.15▲ 93.9% | -2.06▼ 1273.3% | -2.18▲ 0% |
EPS Growth % | -116.52% | 43.51% | -7.3% | 34.69% | -77.08% | 45.88% | -32.61% | 93.85% | -1273.33% | -167.34% |
EPS (Basic) | -4.85 | -2.74 | -2.94 | -1.92 | -3.40 | -1.84 | -2.44 | -1.54 | -2.06 | - |
Diluted Shares Outstanding | 252.82K | 312.55K | 379.41K | 17.75M | 27.38M | 30.86M | 39.16M | 704.61M | 89.33M | 108.79M |
Basic Shares Outstanding | 252.82K | 312.55K | 379.41K | 17.75M | 27.38M | 30.86M | 39.16M | 70.46M | 89.33M | 108.79M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
MNMD Balance Sheet
Mind Medicine (MindMed) Inc. (MNMD) balance sheet — assets, liabilities & shareholders' equity
| Metric | Aug'17 | Aug'18 | Aug'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 1.77M | 198.63K | 2.94M | 81.52M | 137.22M | 146.06M | 103.87M | 281.62M | 419.32M | 380.56M |
Cash & Short-Term Investments | 1.69M | 154.79K | 17.93K | 80.09M | 133.54M | 142.14M | 99.7M | 273.74M | 411.59M | 373.42M |
Cash Only | 3.98K | 154.79K | 17.93K | 80.09M | 133.54M | 142.14M | 99.7M | 273.74M | 257.84M | 262.52M |
Short-Term Investments | 1.69M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 153.76M | 110.9M |
Accounts Receivable | 10.28K | 8.24K | 5.08K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
Inventory | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | 0.05 | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 2.91M | 0 | 0 | 0 | 4.17M | 7.88M | 7.73M | 7.14M |
Total Non-Current Assets | 2.26M | 3.33M | 0 | 0 | 26.79M | 23.94M | 20.67M | 20.53M | 20.78M | 20.73M |
Property, Plant & Equipment | 70.5K | 63.88K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | - |
Goodwill | 0 | 0 | 0 | 0 | 19.92M | 19.92M | 19.92M | 19.92M | 19.92M | 19.92M |
Intangible Assets | 0 | 0 | 0 | 0 | 6.87M | 3.69M | 527K | 0 | 0 | 0 |
Long-Term Investments | 69.99K | 136K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 54.86M |
Other Non-Current Assets | 2.12M | 3.13M | 0 | 0 | 0 | 331K | 224K | 613K | 862K | 812K |
Total Assets | 4.03M▲ 0% | 3.53M▼ 12.3% | 2.94M▼ 16.9% | 81.52M▲ 2675.7% | 164M▲ 101.2% | 169.99M▲ 3.7% | 124.54M▼ 26.7% | 302.15M▲ 142.6% | 440.1M▲ 45.7% | 401.29M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | 1886.43% | -12.28% | -16.87% | 2675.66% | 101.18% | 3.65% | -26.74% | 142.61% | 45.66% | 64.36% |
Total Current Liabilities | 80.44K | 8.23K | 198.96K | 3.01M | 10.41M | 17.89M | 32.25M | 38.85M | 66.7M | 81.11M |
Accounts Payable | 0 | 0 | 0 | 2.02M | 4.18M | 2.11M | 4.14M | 2.01M | 5.35M | 7.13M |
Days Payables Outstanding | - | - | - | - | - | 239.07 | 477.43 | 1.39K | - | - |
Short-Term Debt | 15.74K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 64.7K | 8.23K | 198.96K | -462K | 2.29M | 13.03M | 20.74M | 30.41M | 61.35M | 73.98M |
Current Ratio | 22.03x | 24.14x | 14.76x | 27.10x | 13.18x | 8.16x | 3.22x | 7.25x | 6.29x | 4.69x |
Quick Ratio | 22.03x | 24.14x | 14.76x | 27.10x | 13.18x | 8.16x | 3.22x | 7.25x | 6.29x | 4.69x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 0 | 0 | 0 | 2.64M | 1.93M | 1.18M | 14.16M | 21.85M | 41.08M | 41.33M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 14.13M | 21.85M | 0 | 40.77M |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 2.64M | 1.93M | 1.18M | 32K | 0 | 41.08M | 559K |
Total Liabilities | 80.44K | 8.23K | 198.96K | 5.65M | 12.34M | 19.08M | 46.41M | 60.7M | 107.77M | 122.44M |
Total Debt | 15.74K | 0 | 0 | 0 | 0 | 72K | 14.13M | 21.85M | 0 | 40.77M |
Net Debt | 11.77K | -154.79K | -17.93K | -80.09M | -133.54M | -142.07M | -85.58M | -251.89M | -257.84M | -221.75M |
Debt / Equity | 0.00x | - | - | - | - | 0.00x | 0.18x | 0.09x | - | 0.15x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.21x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 1.16x |
Interest Coverage | - | - | - | -205.93x | -261.43x | -44.37x | -104.06x | -46.60x | -32.53x | -22.33x |
Total Equity | 3.95M▲ 0% | 3.52M▼ 10.7% | 2.74M▼ 22.3% | 75.87M▲ 2671.0% | 151.66M▲ 99.9% | 150.92M▼ 0.5% | 78.13M▼ 48.2% | 241.45M▲ 209.0% | 332.33M▲ 37.6% | 278.85M▲ 0% |
Equity Growth % | 3001.1% | -10.7% | -22.32% | 2670.96% | 99.91% | -0.49% | -48.23% | 209.02% | 37.64% | 4.36% |
Book Value per Share | 15.61 | 11.28 | 7.22 | 4.27 | 5.54 | 4.89 | 2.00 | 0.34 | 3.72 | 2.56 |
Total Shareholders' Equity | 3.95M | 3.52M | 2.74M | 75.87M | 151.66M | 150.92M | 78.13M | 241.45M | 332.33M | 278.85M |
Common Stock | 5.16M | 5.32M | 5.56M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Retained Earnings | -1.81M | -2.59M | -3.65M | -44.64M | -137.67M | -194.47M | -290.2M | -398.88M | -582.67M | -659.77M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -41.38K | 19.14K | 34.69K | 284K | 1.05M | 627K | 343K | 819K | 1.08M | 824K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MNMD Cash Flow Statement
Mind Medicine (MindMed) Inc. (MNMD) cash flow — operating, investing & free cash flow history
| Metric | Aug'17 | Aug'18 | Aug'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -665.98K | -722.45K | -208.12K | -23.6M | -45.82M | -50.14M | -64.36M | -79.13M | -131.56M | -143.69M |
Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
Operating CF Growth % | -2400.32% | -8.48% | 71.19% | -11238.22% | -94.19% | -9.42% | -28.37% | -22.94% | -66.26% | -230.22% |
Net Income | -1.23M | -857.94K | -1.12M | -33.94M | -93.04M | -56.8M | -95.73M | -108.68M | -183.79M | -237.54M |
Depreciation & Amortization | 5.5K | 6.68K | 6.68K | 0 | 2.62M | 3.18M | 3.16M | 527K | 0 | 631K |
Stock-Based Compensation | 0 | 0 | 0 | 7.41M | 42.72M | 13.71M | 15.49M | 16.91M | 20.1M | 29.62M |
Deferred Taxes | 0 | 0 | 0 | 0 | -1.16M | 0 | -2.02M | 0 | 0 | 0 |
Other Non-Cash Items | 652.92K | 160.96K | 703.52K | 873K | 1.16M | -6.45M | 8.46M | 15.45M | 22.7M | 46.45M |
Working Capital Changes | -81.76K | -20.46K | 207.83K | 2.06M | 1.88M | -3.78M | 6.28M | -3.34M | 9.44M | 17.16M |
Change in Receivables | -4.91K | 1.68K | 3.02K | -13K | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 13K | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 0 | 0 | 544K | 1.28M | -2.06M | 2.02M | -2.13M | 3.34M | 4.77M |
Cash from Investing | -3.67M | 541.34K | -213.15K | 0 | -297K | 0 | 0 | 0 | -151.61M | 55.4M |
Capital Expenditures | -2.15M | -1.04M | -313.46K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | -297K | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 30.44K | 0 | 100.3K | 0 | 0 | 0 | 0 | 0 | 0 | 20.89M |
Cash from Financing | 4.35M | 312.05K | 288.36K | 96.7M | 98.82M | 59.05M | 21.85M | 253.2M | 267.27M | 272.32M |
Debt Issued (Net) | 14.95K | -15.45K | 0 | 0 | 0 | 0 | 14.16M | 10.86M | 19.55M | 20.1M |
Equity Issued (Net) | 4.34M | 327.5K | 288.36K | 71.99M | 81.92M | 42.3M | 7.53M | 250M | 247.72M | 251.79M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | 0 | 24.71M | 16.9M | 16.75M | 163K | -7.66M | 0 | 440.88K |
Net Change in Cash | -6.98K▲ 0% | 150.81K▲ 2259.4% | -136.86K▼ 190.7% | 73.39M▲ 53724.9% | 53.45M▼ 27.2% | 8.6M▼ 83.9% | -42.44M▼ 593.3% | 174.04M▲ 510.1% | -15.9M▼ 109.1% | 179.66M▲ 0% |
Free Cash Flow | -2.82M▲ 0% | -1.77M▲ 37.3% | -521.58K▲ 70.5% | -23.6M▼ 4424.2% | -45.82M▼ 94.2% | -50.14M▼ 9.4% | -64.36M▼ 28.4% | -79.13M▼ 22.9% | -131.56M▼ 66.3% | -174.34M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - | - | - |
FCF Growth % | -4862.73% | 37.27% | 70.47% | -4424.17% | -94.19% | -9.42% | -28.37% | -22.94% | -66.26% | -89.6% |
FCF per Share | -11.14 | -5.65 | -1.37 | -1.33 | -1.67 | -1.62 | -1.64 | -0.11 | -1.47 | -1.60 |
FCF Conversion (FCF/Net Income) | 0.54x | 0.84x | 0.19x | 0.69x | 0.49x | 0.88x | 0.67x | 0.73x | 0.72x | 0.73x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.22M | 0 | 4.04M |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MNMD Key Ratios
Mind Medicine (MindMed) Inc. (MNMD) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -60.22% | -22.96% | -35.63% | -86.76% | -81.78% | -37.54% | -83.59% | -68.01% | -64.06% | -102.48% |
Return on Invested Capital (ROIC) | -45.46% | -17.64% | -11.53% | - | -1012.89% | -368.89% | -10014.15% | - | -389.48% | -133.23% |
Debt / Equity | 0.00x | - | - | - | - | 0.00x | 0.18x | 0.09x | - | 0.15x |
Interest Coverage | - | - | - | -205.93x | -261.43x | -44.37x | -104.06x | -46.60x | -32.53x | -22.33x |
FCF Conversion | 0.54x | 0.84x | 0.19x | 0.69x | 0.49x | 0.88x | 0.67x | 0.73x | 0.72x | 0.73x |
Related:MNMD Dividend History·MNMD Revenue History·MNMD Price History·MNMD P/E History·MNMD Financial Ratios·MNMD Institutional Holders
MNMD SEC Filings & Documents
Mind Medicine (MindMed) Inc. (MNMD) SEC filings — annual & quarterly reports (10-K, 10-Q)
MNMD Frequently Asked Questions
Mind Medicine (MindMed) Inc. (MNMD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Mind Medicine (MindMed) Inc. (MNMD) grew revenue by 0.0% over the past year. Growth has been modest.
Mind Medicine (MindMed) Inc. (MNMD) reported a net loss of $237.5M for fiscal year 2025.
Dividend & Returns
Mind Medicine (MindMed) Inc. (MNMD) has a return on equity (ROE) of -64.1%. Negative ROE indicates the company is unprofitable.
Mind Medicine (MindMed) Inc. (MNMD) had negative free cash flow of $174.3M in fiscal year 2025, likely due to heavy capital investments.